CareDx, Inc(NASDAQ:CDNA) 
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant pati...
Website: https://caredx.com/
Founded: 1998
Full Time Employees: 306
CEO: Reginald Seeto
Sector: Healthcare
Industry: Diagnostics & Research
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||
testing services revenue | 91,398,000 | 78,373,000 | 72,168,000 | 62,033,000 | 61,921,000 | 63,819,000 | 60,807,000 | 70,918,000 | 53,837,000 | 46,703,000 | 47,784,000 | 53,414,000 | 61,784,000 | 65,418,000 | 64,751,000 | 67,135,000 | 66,444,000 | 68,650,000 | 66,464,000 | 64,890,000 | 59,281,000 | 50,346,000 | 45,529,000 | 36,293,000 | 31,442,000 | 29,129,000 | 28,226,000 | 25,677,000 | 21,518,000 | 4,211,750 | 16,847,000 | 13,997,000 | ||||||||||||||||
product revenue | 10,346,000 | 13,256,000 | 12,478,000 | 11,833,000 | 10,810,000 | 11,367,000 | 10,212,000 | 10,610,000 | 8,594,000 | 9,244,000 | 9,536,000 | 7,876,000 | 6,861,000 | 8,555,000 | 7,194,000 | 6,714,000 | 6,788,000 | 7,672,000 | 6,521,000 | 6,861,000 | 5,778,000 | 5,933,000 | 5,383,000 | 3,291,000 | 4,695,000 | 5,053,000 | 4,200,000 | 4,593,000 | 4,433,000 | 11,451,000 | 4,223,000 | 3,550,000 | 3,307,000 | 10,762,000 | 3,872,000 | 3,376,000 | 3,667,000 | 3,487,000 | 3,754,000 | 3,475,000 | ||||||||
patient and digital solutions revenue | 15,956,000 | 16,757,000 | 15,409,000 | 12,813,000 | 11,954,000 | 8,057,000 | 11,864,000 | 10,746,000 | 9,618,000 | 6,875,000 | 9,872,000 | 9,011,000 | 8,617,000 | 5,095,750 | 7,414,000 | 6,785,000 | 6,184,000 | |||||||||||||||||||||||||||||||
total revenue | 117,700,000 | 108,386,000 | 100,055,000 | 86,679,000 | 84,685,000 | 86,579,000 | 82,883,000 | 92,274,000 | 72,049,000 | 65,569,000 | 67,192,000 | 70,301,000 | 77,262,000 | 82,384,000 | 79,359,000 | 80,634,000 | 79,416,000 | 79,220,000 | 75,589,000 | 74,188,000 | 67,400,000 | 58,644,000 | 53,369,000 | 41,801,000 | 38,380,000 | 35,821,000 | 33,811,000 | 31,454,000 | 25,982,000 | 55,385,000 | 21,184,000 | 17,823,000 | 14,053,000 | 36,133,000 | 12,191,000 | 12,046,000 | 11,584,000 | 10,860,000 | 12,475,000 | 10,735,000 | 6,562,000 | 6,648,000 | 7,151,000 | 7,129,000 | 7,216,000 | 7,952,000 | 6,654,000 | 6,776,000 |
yoy | 38.99% | 25.19% | 20.72% | -6.06% | 17.54% | 32.04% | 23.35% | 31.26% | -6.75% | -20.41% | -15.33% | -12.81% | -2.71% | 3.99% | 4.99% | 8.69% | 17.83% | 35.09% | 41.63% | 77.48% | 75.61% | 63.71% | 57.85% | 32.90% | 47.72% | -35.32% | 59.61% | 76.48% | 84.89% | 53.28% | 73.77% | 47.96% | 21.31% | 232.72% | -2.28% | 12.21% | 76.53% | 63.36% | 74.45% | 50.58% | -9.06% | -16.40% | 7.47% | 5.21% | ||||
qoq | 8.59% | 8.33% | 15.43% | 2.35% | -2.19% | 4.46% | -10.18% | 28.07% | 9.88% | -2.42% | -4.42% | -9.01% | -6.22% | 3.81% | -1.58% | 1.53% | 0.25% | 4.80% | 1.89% | 10.07% | 14.93% | 9.88% | 27.67% | 8.91% | 7.14% | 5.94% | 7.49% | 21.06% | -53.09% | 161.45% | 18.86% | 26.83% | -61.11% | 196.39% | 1.20% | 3.99% | 6.67% | -12.95% | 16.21% | 63.59% | -1.29% | -7.03% | 0.31% | -1.21% | -9.26% | 19.51% | -1.80% | |
operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||
cost of testing services | 17,097,000 | 16,821,000 | 14,705,000 | 15,406,000 | 15,113,000 | 14,224,000 | 13,447,000 | 14,308,000 | 13,632,000 | 13,805,000 | 13,217,000 | 15,324,000 | 15,296,000 | 18,657,000 | 17,771,000 | 18,230,000 | 17,628,000 | 19,495,000 | 18,038,000 | 17,235,000 | 16,483,000 | 13,301,000 | 11,900,000 | 6,838,000 | 15,704,000 | 5,752,000 | 4,568,000 | |||||||||||||||||||||
cost of product | 4,834,000 | 6,757,000 | 5,629,000 | 4,981,000 | 5,586,000 | 5,580,000 | 6,212,000 | 6,245,000 | 5,344,000 | 5,637,000 | 4,750,000 | 3,926,000 | 4,066,000 | 4,617,000 | 4,736,000 | 3,887,000 | 4,399,000 | 5,159,000 | 4,919,000 | 5,205,000 | 3,647,000 | 4,212,000 | 3,705,000 | 2,895,000 | 8,396,000 | 3,135,000 | 2,639,000 | 2,272,000 | 6,973,000 | 2,053,000 | 2,178,000 | 2,327,000 | 3,829,000 | 3,355,000 | 3,056,000 | |||||||||||||
cost of patient and digital solutions | 11,698,000 | 11,934,000 | 10,320,000 | 8,271,000 | 7,716,000 | 8,374,000 | 7,913,000 | 7,393,000 | 6,958,000 | 6,171,000 | 6,566,000 | 6,637,000 | 6,604,000 | 6,216,000 | 5,794,000 | 5,422,000 | 4,855,000 | |||||||||||||||||||||||||||||||
research and development | 21,416,000 | 19,306,000 | 16,769,000 | 16,830,000 | 18,524,000 | 16,530,000 | 17,486,000 | 19,678,000 | 18,711,000 | 18,276,000 | 19,000,000 | 20,233,000 | 24,357,000 | 23,570,000 | 22,306,000 | 22,632,000 | 21,880,000 | 22,046,000 | 19,439,000 | 19,036,000 | 16,004,000 | 13,325,000 | 12,474,000 | 13,129,000 | 10,013,000 | 8,946,000 | 8,521,000 | 7,630,000 | 5,614,000 | 10,646,000 | 3,868,000 | 3,496,000 | 3,368,000 | 9,429,000 | 2,959,000 | 3,118,000 | 3,283,000 | 3,154,000 | 2,930,000 | 3,143,000 | 3,159,000 | 2,704,000 | 2,698,000 | 2,510,000 | 1,421,000 | 1,298,000 | 1,036,000 | 792,000 |
sales and marketing | 30,373,000 | 30,924,000 | 24,449,000 | 24,279,000 | 22,991,000 | 21,084,000 | 19,802,000 | 21,002,000 | 19,830,000 | 19,999,000 | 18,474,000 | 21,630,000 | 23,231,000 | 23,668,000 | 22,261,000 | 26,950,000 | 23,148,000 | 20,824,000 | 21,370,000 | 19,599,000 | 15,452,000 | 16,131,000 | 13,870,000 | 12,134,000 | 11,723,000 | 10,267,000 | 11,058,000 | 10,644,000 | 6,925,000 | 15,699,000 | 5,971,000 | 5,860,000 | 4,085,000 | 9,553,000 | 3,255,000 | 3,270,000 | 3,222,000 | 2,622,000 | 3,451,000 | 3,356,000 | 1,737,000 | 1,896,000 | 2,062,000 | 2,526,000 | 2,023,000 | 1,635,000 | 1,753,000 | 1,610,000 |
general and administrative | 30,484,000 | 28,684,000 | 28,429,000 | 27,683,000 | 22,769,000 | 40,680,000 | 28,515,000 | 27,678,000 | 26,911,000 | 26,541,000 | 33,968,000 | 29,327,000 | 28,032,000 | 24,776,000 | 23,830,000 | 25,232,000 | 26,559,000 | 24,748,000 | 18,671,000 | 16,322,000 | 15,223,000 | 13,370,000 | 13,117,000 | 12,316,000 | 10,003,000 | 9,437,000 | 9,485,000 | 8,512,000 | 9,106,000 | 16,782,000 | 5,177,000 | 5,596,000 | 5,307,000 | 14,875,000 | 4,038,000 | 4,132,000 | 6,502,000 | 4,475,000 | 5,180,000 | 5,393,000 | 5,676,000 | 3,694,000 | 3,361,000 | 2,329,000 | 2,705,000 | 2,349,000 | 1,976,000 | 2,316,000 |
litigation settlement expense | 600,000 | 350,000 | 5,360,000 | |||||||||||||||||||||||||||||||||||||||||||||
total operating expenses | 116,502,000 | 114,426,000 | 100,301,000 | 97,800,000 | 98,059,000 | 11,887,000 | 93,375,000 | 96,372,000 | 91,386,000 | 188,201,000 | 95,975,000 | 97,925,000 | 101,586,000 | 101,504,000 | 96,698,000 | 102,353,000 | 98,469,000 | 94,619,000 | 84,316,000 | 78,930,000 | 68,258,000 | 61,711,000 | 56,276,000 | 37,579,000 | 31,739,000 | 28,650,000 | 29,064,000 | 26,786,000 | 31,378,000 | 68,244,000 | 23,903,000 | 23,032,000 | 19,288,000 | 52,563,000 | 16,055,000 | 15,645,000 | 20,128,000 | 29,721,000 | 17,408,000 | 17,703,000 | 13,131,000 | 11,111,000 | 10,344,000 | 10,015,000 | 8,607,000 | 7,523,000 | 5,261,000 | 7,121,000 |
income from operations | 1,198,000 | -6,040,000 | -246,000 | -11,121,000 | -13,374,000 | 74,692,000 | -10,492,000 | -4,098,000 | -19,337,000 | -122,632,000 | -28,783,000 | -27,624,000 | -24,324,000 | -19,120,000 | -17,339,000 | -21,719,000 | -19,053,000 | -15,399,000 | -8,727,000 | -4,742,000 | -858,000 | -3,067,000 | -2,907,000 | -10,803,000 | -5,751,000 | -5,545,000 | -6,747,000 | -6,844,000 | -5,396,000 | -12,859,000 | -2,719,000 | -5,209,000 | -5,235,000 | -16,430,000 | -3,864,000 | -3,599,000 | -8,544,000 | -18,861,000 | -4,933,000 | -6,968,000 | -6,569,000 | -4,463,000 | -3,193,000 | -2,886,000 | -1,391,000 | 429,000 | 1,393,000 | -345,000 |
yoy | -108.96% | -108.09% | -97.66% | 171.38% | -30.84% | -160.91% | -63.55% | -85.17% | -20.50% | 541.38% | 66.00% | 27.19% | 27.66% | 24.16% | 98.68% | 358.01% | 2120.63% | 402.09% | 200.21% | -56.10% | -85.08% | -44.69% | -56.91% | 57.85% | 6.58% | -56.88% | 148.14% | 31.39% | 3.08% | -21.73% | -29.63% | 44.73% | -38.73% | -12.89% | -21.67% | -48.35% | 30.07% | 322.61% | 54.49% | 141.44% | 372.25% | -1140.33% | -329.22% | 736.52% | ||||
qoq | -119.83% | 2355.28% | -97.79% | -16.85% | -117.91% | -811.89% | 156.03% | -78.81% | -84.23% | 326.06% | 4.20% | 13.57% | 27.22% | 10.27% | -20.17% | 13.99% | 23.73% | 76.45% | 84.04% | 452.68% | -72.02% | 5.50% | -73.09% | 87.85% | 3.72% | -17.82% | -1.42% | 26.83% | -58.04% | 372.93% | -47.80% | -0.50% | -68.14% | 325.21% | 7.36% | -57.88% | -54.70% | 282.34% | -29.20% | 6.07% | 47.19% | 39.77% | 10.64% | 107.48% | -424.24% | -69.20% | -503.77% | |
operating margin % | 1.02% | -5.57% | -0.25% | -12.83% | -15.79% | 86.27% | -12.66% | -4.44% | -26.84% | -187.03% | -42.84% | -39.29% | -31.48% | -23.21% | -21.85% | -26.94% | -23.99% | -19.44% | -11.55% | -6.39% | -1.27% | -5.23% | -5.45% | -25.84% | -14.98% | -15.48% | -19.96% | -21.76% | -20.77% | -23.22% | -12.84% | -29.23% | -37.25% | -45.47% | -31.70% | -29.88% | -73.76% | -173.67% | -39.54% | -64.91% | -100.11% | -67.13% | -44.65% | -40.48% | -19.28% | 5.39% | 20.93% | -5.09% |
other income: | ||||||||||||||||||||||||||||||||||||||||||||||||
interest income | 1,909,000 | 2,013,000 | 2,013,000 | 2,364,000 | 2,784,000 | 3,053,000 | 3,001,000 | 2,826,000 | 2,885,000 | 3,159,000 | 3,171,000 | 2,871,000 | 2,666,000 | 1,870,000 | 1,225,000 | 478,000 | 189,000 | 13,000 | 20,000 | 1,000 | 126,000 | 125,000 | 29,000 | 21,000 | 96,000 | 306,000 | 37,000 | 300,000 | 342,000 | |||||||||||||||||||
other income | -330,000 | 264,000 | -107,000 | 72,000 | 295,000 | 436,000 | 283,000 | 1,541,000 | 2,047,000 | -553,000 | 2,779,000 | -2,917,000 | -46,000 | -45,000 | -43,000 | -45,000 | 355,000 | 366,000 | ||||||||||||||||||||||||||||||
total other income | 1,579,000 | 2,277,000 | 1,906,000 | 2,436,000 | 3,079,000 | 3,489,000 | 3,284,000 | 2,726,000 | 2,595,000 | 4,700,000 | 5,218,000 | 2,603,000 | 699,000 | 964,000 | 667,000 | -27,000 | -1,653,000 | -3,332,000 | 2,715,000 | -619,000 | -146,000 | 3,915,000 | 564,000 | 3,985,000 | -1,223,000 | -2,741,000 | ||||||||||||||||||||||
income before income taxes | 2,777,000 | -3,763,000 | 1,660,000 | -8,685,000 | -10,295,000 | 78,181,000 | -7,208,000 | -1,372,000 | -16,742,000 | -117,932,000 | -23,565,000 | -25,021,000 | -23,625,000 | -18,156,000 | -16,672,000 | -21,746,000 | -19,660,000 | -17,052,000 | -12,059,000 | -2,027,000 | -950,000 | -3,686,000 | -3,053,000 | -6,888,000 | -6,123,000 | -4,981,000 | -2,762,000 | -8,067,000 | -8,137,000 | -27,955,000 | -20,260,000 | -14,443,000 | -9,418,000 | -42,804,000 | -14,465,000 | -4,411,000 | -5,892,000 | -16,427,000 | -4,248,000 | -10,933,000 | -4,762,000 | -3,489,000 | -3,185,000 | -5,000 | 1,213,000 | -623,000 | ||
income tax benefit | 32,000 | 18,500 | 15,000 | 117,000 | -58,000 | -34,750 | -200,000 | -22,000 | 83,000 | -165,000 | 80,000 | 68,000 | -124,000 | -173,000 | -267,000 | 49,000 | 12,000 | 901,000 | 162,000 | 100,000 | 263,000 | 171,000 | 235,000 | 330,000 | 300,000 | 204,000 | 949,000 | 220,000 | 606,000 | 1,144,000 | 290,000 | 381,000 | 424,000 | 1,531,000 | 178,000 | 376,000 | 283,000 | 718,000 | 449,000 | 440,000 | 1,500,000 | |||||||
net income | 2,809,000 | -4,108,000 | 1,675,000 | -8,568,000 | -10,353,000 | 78,010,000 | -7,408,000 | -1,394,000 | -16,659,000 | -118,097,000 | -23,485,000 | -24,953,000 | -23,749,000 | -18,329,000 | -16,939,000 | -21,697,000 | -19,648,000 | -16,151,000 | -11,897,000 | -1,927,000 | -687,000 | -3,515,000 | -2,818,000 | -6,558,000 | -5,823,000 | -4,777,000 | -1,813,000 | -7,847,000 | -7,531,000 | -26,811,000 | -19,970,000 | -14,062,000 | -8,994,000 | -41,273,000 | -14,287,000 | -4,035,000 | -5,609,000 | -15,709,000 | -3,799,000 | -10,493,000 | -9,752,000 | -4,762,000 | -3,489,000 | -3,185,000 | -2,272,000 | -5,000 | 1,213,000 | 877,000 |
yoy | -127.13% | -105.27% | -122.61% | 514.63% | -37.85% | -166.06% | -68.46% | -94.41% | -29.85% | 544.32% | 38.64% | 15.01% | 20.87% | 13.49% | 42.38% | 1025.95% | 2759.97% | 359.49% | 322.18% | -70.62% | -88.20% | -26.42% | 55.43% | -16.43% | -22.68% | -82.18% | -90.92% | -44.20% | -16.27% | -35.04% | 39.78% | 248.50% | 60.35% | 162.73% | 276.07% | -61.55% | -42.48% | 229.88% | 8.89% | 229.45% | 329.23% | 95140.00% | -387.63% | -463.17% | ||||
qoq | -168.38% | -345.25% | -119.55% | -17.24% | -113.27% | -1153.05% | 431.42% | -91.63% | -85.89% | 402.86% | -5.88% | 5.07% | 29.57% | 8.21% | -21.93% | 10.43% | 21.65% | 35.76% | 517.38% | 180.49% | -80.46% | 24.73% | -57.03% | 12.62% | 21.90% | 163.49% | -76.90% | 4.20% | -71.91% | 34.26% | 42.01% | 56.35% | -78.21% | 188.89% | 254.08% | -28.06% | -64.29% | 313.50% | -63.79% | 7.60% | 104.79% | 36.49% | 9.54% | 40.18% | 45340.00% | -100.41% | 38.31% | |
net income margin % | 2.39% | -3.79% | 1.67% | -9.88% | -12.23% | 90.10% | -8.94% | -1.51% | -23.12% | -180.11% | -34.95% | -35.49% | -30.74% | -22.25% | -21.34% | -26.91% | -24.74% | -20.39% | -15.74% | -2.60% | -1.02% | -5.99% | -5.28% | -15.69% | -15.17% | -13.34% | -5.36% | -24.95% | -28.99% | -48.41% | -94.27% | -78.90% | -64.00% | -114.23% | -117.19% | -33.50% | -48.42% | -144.65% | -30.45% | -97.75% | -148.61% | -71.63% | -48.79% | -44.68% | -31.49% | -0.06% | 18.23% | 12.94% |
net income per share | ||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.05 | -0.08 | 0.03 | -0.16 | -0.19 | 1.49 | -0.14 | -0.03 | -0.32 | -2.2 | -0.43 | -0.46 | -0.44 | -0.35 | -0.32 | -0.41 | -0.37 | -0.31 | -0.23 | -0.04 | -0.01 | -0.07 | -0.06 | -0.15 | -0.14 | -0.11 | -0.04 | -0.19 | -0.18 | -0.77 | -0.54 | -0.4 | -0.3 | -1.75 | -0.63 | -0.19 | -0.26 | -0.78 | -0.2 | -0.4 | -0.29 | -0.27 | -0.08 | 0.13 | 0.87 | |||
diluted | 0.05 | -0.08 | 0.03 | -0.16 | -0.19 | 1.42 | -0.14 | -0.03 | -0.32 | -2.2 | -0.43 | -0.46 | -0.44 | -0.35 | -0.32 | -0.41 | -0.37 | -0.31 | -0.23 | -0.04 | -0.01 | -0.07 | -0.06 | -0.15 | -0.14 | -0.11 | -0.04 | -0.19 | -0.18 | -0.77 | -0.54 | -0.4 | -0.3 | -1.75 | -0.63 | -0.19 | -0.26 | -0.78 | -0.26 | -0.4 | -0.29 | -0.27 | -0.01 | 0.12 | 0.13 | |||
weighted-average shares used for eps calculation | ||||||||||||||||||||||||||||||||||||||||||||||||
basic | 51,151,794 | 53,287,546 | 52,507,582 | 54,304,754 | 55,262,459 | 52,773,247 | 52,903,338 | 52,195,620 | 51,692,358 | 53,764,705 | 54,178,759 | 53,846,260 | 53,643,216 | 53,321,625 | 53,489,418 | 53,249,545 | 53,015,459 | 52,241,076 | 52,681,451 | 52,224,300 | 51,181,160 | 46,481,772 | 49,010,680 | 44,708,037 | 42,823,427 | 42,151,617 | 42,393,550 | 42,132,396 | 41,611,399 | 35,638,956 | 37,154,293 | 35,549,837 | 29,615,441 | 23,332,503 | 22,526,615 | 21,412,480 | 21,343,782 | 16,496,911 | 19,098,626 | |||||||||
diluted | 53,129,928 | 53,287,546 | 53,736,790 | 54,304,754 | 55,262,459 | 56,620,590 | 52,903,338 | 52,195,620 | 51,692,358 | 53,764,705 | 54,178,759 | 53,846,260 | 53,643,216 | 53,321,625 | 53,489,418 | 53,249,545 | 53,015,459 | 52,241,076 | 52,681,451 | 52,224,300 | 51,181,160 | 46,481,772 | 49,010,680 | 44,708,037 | 42,823,427 | 42,151,617 | 42,393,550 | 42,132,396 | 41,611,399 | 35,638,956 | 37,154,293 | 35,549,837 | 29,615,441 | 23,332,503 | 22,526,615 | 21,412,480 | 21,343,782 | 16,496,911 | 19,481,424 | |||||||||
restructuring costs | 1,715,000 | 68,000 | 1,472,000 | 848,000 | ||||||||||||||||||||||||||||||||||||||||||||
change in estimated fair value of common stock warrant liability | 3,000 | 7,000 | 18,000 | 14,000 | 48,000 | 27,000 | 56,000 | 88,000 | -65,000 | 27,000 | -247,500 | 79,000 | -664,000 | -405,000 | -444,750 | 1,386,000 | -3,165,000 | |||||||||||||||||||||||||||||||
other expense | -100,000 | -290,000 | -271,000 | -1,974,000 | -924,000 | -572,000 | -823,000 | -1,722,000 | -3,440,000 | -245,000 | -239,000 | -254,000 | -255,000 | -63,000 | -75,000 | -398,000 | -172,000 | -74,000 | -138,000 | -40,000 | -42,000 | -2,809,000 | -1,173,000 | -317,000 | -188,000 | -686,000 | -833,500 | -133,000 | -274,000 | -54,000 | ||||||||||||||||||
total other expense | -607,000 | -92,000 | -372,000 | |||||||||||||||||||||||||||||||||||||||||||||
digital and other revenue | 1,845,500 | 2,604,000 | 2,437,000 | 2,341,000 | 2,365,000 | 2,457,000 | 2,217,000 | 2,243,000 | 1,639,000 | 1,385,000 | 1,184,000 | |||||||||||||||||||||||||||||||||||||
cost of digital and other | 1,215,250 | 1,879,000 | 1,533,000 | 1,449,000 | 1,372,000 | 1,210,000 | ||||||||||||||||||||||||||||||||||||||||||
cares act provider relief fund | 4,813,000 | |||||||||||||||||||||||||||||||||||||||||||||||
cost of revenue | 15,025,000 | 12,392,000 | 12,716,000 | 11,494,000 | 11,512,000 | |||||||||||||||||||||||||||||||||||||||||||
gross profit | 26,776,000 | 25,988,000 | 23,105,000 | 22,317,000 | 19,942,000 | |||||||||||||||||||||||||||||||||||||||||||
yoy | 34.27% | |||||||||||||||||||||||||||||||||||||||||||||||
qoq | 3.03% | 12.48% | 3.53% | 11.91% | ||||||||||||||||||||||||||||||||||||||||||||
gross margin % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 64.06% | 67.71% | 64.50% | 66.01% | 63.40% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
change in estimated fair value of contingent consideration | 873,000 | 144,000 | 586,000 | 594,000 | -64,000 | -221,000 | -34,000 | -112,000 | -97,000 | -213,000 | 330,000 | -345,000 | 142,000 | -253,000 | 37,000 | -1,276,000 | ||||||||||||||||||||||||||||||||
debt extinguishment expenses | ||||||||||||||||||||||||||||||||||||||||||||||||
change in estimated fair value of common stock warrant liability and derivative liability | -3,500 | 4,346,000 | -1,351,000 | -3,009,000 | -4,273,250 | -17,093,000 | -8,768,000 | 1,321,000 | -2,149,750 | -8,599,000 | 1,067,000 | 4,128,000 | ||||||||||||||||||||||||||||||||||||
net loss attributable to noncontrolling interest | -25,000 | -72,000 | -19,000 | -67,000 | -47,000 | 14,500 | 35,000 | 23,000 | ||||||||||||||||||||||||||||||||||||||||
net loss attributable to caredx, inc. | -4,777,000 | -1,813,000 | -7,847,000 | -7,531,000 | -26,786,000 | -19,970,000 | -14,062,000 | -8,969,000 | -41,201,000 | -14,268,000 | -3,968,000 | -5,562,000 | -5,997,250 | -3,764,000 | -10,470,000 | |||||||||||||||||||||||||||||||||
license and other revenue | 31,000 | 481,000 | 114,000 | 276,000 | 142,000 | |||||||||||||||||||||||||||||||||||||||||||
goodwill impairment | 1,958,000 | |||||||||||||||||||||||||||||||||||||||||||||||
interest expense | -3,293,000 | -408,000 | -424,000 | -2,695,000 | -4,178,000 | -1,685,000 | -1,691,000 | -790,000 | -509,000 | -568,000 | -526,000 | -266,000 | -253,000 | -251,000 | -256,000 | -827,000 | -389,000 | -535,000 | -644,000 | |||||||||||||||||||||||||||||
testing revenue | 10,604,000 | 24,943,000 | 8,163,000 | 8,420,000 | 7,902,000 | 7,363,000 | 8,613,000 | 7,249,000 | 6,452,000 | 6,734,000 | 7,007,000 | 7,044,000 | 7,096,000 | 6,697,000 | 6,601,000 | 6,710,000 | ||||||||||||||||||||||||||||||||
cost of testing | 4,112,000 | 9,189,000 | 3,156,000 | 3,011,000 | 3,057,000 | 2,654,000 | 2,604,000 | 2,852,000 | 2,772,000 | 2,487,000 | 2,568,000 | 2,508,000 | 2,711,000 | 2,204,000 | 1,772,000 | 2,403,000 | ||||||||||||||||||||||||||||||||
collaboration, license and other revenue | 39,000 | 156,000 | 250,000 | 15,000 | 56,500 | 108,000 | 11,000 | 110,000 | ||||||||||||||||||||||||||||||||||||||||
net income per share | ||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | -0.77 | -0.81 | -0.19 | |||||||||||||||||||||||||||||||||||||||||||||
weighted-average shares used for eps calculation | ||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 13,568,120 | 11,969,714 | ||||||||||||||||||||||||||||||||||||||||||||||
collaboration and license revenue | -86,000 | 144,000 | 85,000 | 120,000 | 1,255,000 | 53,000 | 66,000 | |||||||||||||||||||||||||||||||||||||||||
shares used to compute net income per share: | ||||||||||||||||||||||||||||||||||||||||||||||||
basic | 13,964 | 11,890,057 | 11,835,405 | 2,017,369 | 9,279,649 | 1,013,128 | ||||||||||||||||||||||||||||||||||||||||||
diluted | 13,964 | 11,890,057 | 11,835,405 | 984,098 | 11,219,377 | 6,939,568 | ||||||||||||||||||||||||||||||||||||||||||
shares used to compute net loss per share: | ||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 11,814,467 | |||||||||||||||||||||||||||||||||||||||||||||||
shares used to compute net income per share | ||||||||||||||||||||||||||||||||||||||||||||||||
basic | 13,964 | 11,890,057 | 11,835,405 | 2,017,369 | 9,279,649 | 1,013,128 | ||||||||||||||||||||||||||||||||||||||||||
diluted | 13,964 | 11,890,057 | 11,835,405 | 984,098 | 11,219,377 | 6,939,568 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 77,923,000 | 65,429,000 | 91,435,000 | 68,212,000 | 88,745,000 | 114,689,000 | 95,400,000 | 95,782,000 | 93,299,000 | 82,197,000 | 75,980,000 | 87,786,000 | 74,660,000 | 89,921,000 | 82,959,000 | 166,832,000 | 171,892,000 | 348,485,000 | 353,082,000 | 335,625,000 | 309,324,000 | 134,669,000 | 213,798,000 | 211,409,000 | 32,191,000 | 38,223,000 | 40,927,000 | 43,469,000 | 57,432,000 | 64,616,000 | 26,202,000 | 16,246,000 | 18,695,000 | 16,895,000 | 5,976,000 | 9,104,000 | 12,187,000 | 17,258,000 | 22,265,000 | 17,144,000 | 23,752,000 | 29,888,000 | 33,954,000 | 36,894,000 | 38,985,000 | 36,431,000 | 39,048,000 | 7,872,000 |
marketable securities | 109,253,000 | 111,779,000 | 102,782,000 | 118,043,000 | 142,172,000 | 145,964,000 | 145,453,000 | 133,089,000 | 122,622,000 | 153,221,000 | 192,204,000 | 194,887,000 | 211,279,000 | 203,168,000 | 208,317,000 | 139,388,000 | 147,330,000 | 10,199,000 | 34,317,000 | 64,963,000 | 90,034,000 | |||||||||||||||||||||||||||
accounts receivable | 44,585,000 | 42,628,000 | 47,844,000 | 67,362,000 | 71,485,000 | 64,605,000 | 66,627,000 | 66,161,000 | 60,149,000 | 51,061,000 | 51,694,000 | 51,625,000 | 59,310,000 | 66,312,000 | 70,425,000 | 70,142,000 | 65,320,000 | 59,761,000 | 56,181,000 | 48,066,000 | 43,361,000 | 34,624,000 | 30,610,000 | 27,111,000 | 22,841,000 | 24,057,000 | 19,169,000 | 17,052,000 | 12,525,000 | 9,760,000 | 9,641,000 | 8,072,000 | 6,536,000 | 2,991,000 | 3,270,000 | 3,005,000 | 3,378,000 | 2,768,000 | 4,568,000 | 4,887,000 | 2,512,000 | 2,367,000 | 2,241,000 | 1,706,000 | 1,794,000 | 2,687,000 | 1,749,000 | 1,725,000 |
inventory | 26,404,000 | 26,705,000 | 28,328,000 | 27,915,000 | 22,929,000 | 19,503,000 | 19,263,000 | 19,234,000 | 20,130,000 | 19,471,000 | 17,978,000 | 18,840,000 | 18,018,000 | 19,232,000 | 18,086,000 | 18,861,000 | 18,212,000 | 17,186,000 | 18,800,000 | 15,060,000 | 13,721,000 | 10,012,000 | 9,906,000 | 8,741,000 | 6,947,000 | 6,014,000 | 5,902,000 | 5,341,000 | 5,177,000 | 4,943,000 | 4,621,000 | 4,666,000 | 5,011,000 | 5,529,000 | 6,170,000 | 6,343,000 | 6,048,000 | 5,461,000 | 7,444,000 | 8,651,000 | 595,000 | 766,000 | 814,000 | 731,000 | 775,000 | 686,000 | 496,000 | 614,000 |
prepaid and other current assets | 11,230,000 | 10,591,000 | 29,891,000 | 25,764,000 | 24,908,000 | 7,071,000 | 7,344,000 | 6,343,000 | 6,895,000 | 7,763,000 | 7,310,000 | 7,676,000 | 8,161,000 | 9,216,000 | 8,370,000 | 8,657,000 | 8,733,000 | 7,928,000 | 6,413,000 | 7,928,000 | 7,332,000 | 3,758,000 | 4,345,000 | 4,286,000 | 4,089,000 | 3,628,000 | 2,126,000 | 2,462,000 | 2,444,000 | |||||||||||||||||||
total current assets | 269,395,000 | 257,132,000 | 300,280,000 | 307,296,000 | 350,239,000 | 351,832,000 | 334,087,000 | 320,609,000 | 303,095,000 | 313,713,000 | 345,166,000 | 360,814,000 | 371,428,000 | 387,849,000 | 388,157,000 | 403,880,000 | 411,487,000 | 433,360,000 | 444,675,000 | 440,996,000 | 438,701,000 | 273,097,000 | 258,659,000 | 251,547,000 | 66,068,000 | 71,922,000 | 68,124,000 | 68,324,000 | 77,578,000 | 81,114,000 | 41,943,000 | 30,577,000 | 32,697,000 | 26,767,000 | 16,946,000 | 19,909,000 | 23,076,000 | 26,673,000 | 35,123,000 | 32,461,000 | 27,666,000 | 34,362,000 | 37,969,000 | 40,005,000 | 42,301,000 | 40,346,000 | 42,011,000 | 13,530,000 |
property and equipment | 33,156,000 | 32,971,000 | 30,845,000 | 31,934,000 | 32,729,000 | 33,552,000 | 34,015,000 | 34,202,000 | 34,411,000 | 35,246,000 | 35,355,000 | 36,084,000 | 35,506,000 | 35,529,000 | 34,049,000 | 32,904,000 | 27,564,000 | 22,044,000 | 18,719,000 | 14,219,000 | 11,398,000 | 10,704,000 | 10,144,000 | 7,313,000 | 5,501,000 | 4,430,000 | 3,656,000 | 3,508,000 | 3,820,000 | 4,134,000 | 3,022,000 | 2,360,000 | 2,055,000 | 2,075,000 | 2,281,000 | 2,528,000 | 2,768,000 | 2,931,000 | 3,305,000 | 3,413,000 | 2,346,000 | 2,425,000 | 2,571,000 | 2,559,000 | 2,174,000 | 1,968,000 | 2,049,000 | 1,665,000 |
operating lease right-of-use assets | 21,206,000 | 22,760,000 | ||||||||||||||||||||||||||||||||||||||||||||||
marketable securities, non-current | 10,901,000 | 24,165,000 | ||||||||||||||||||||||||||||||||||||||||||||||
intangible assets | 32,102,000 | 31,960,000 | 33,446,000 | 36,037,000 | 37,247,000 | 38,184,000 | 40,361,000 | 41,896,000 | 43,330,000 | 45,701,000 | 46,455,000 | 43,529,000 | 45,637,000 | 43,051,000 | 43,855,000 | 46,318,000 | 48,149,000 | 50,195,000 | 48,367,000 | 48,432,000 | 45,457,000 | 44,355,000 | 43,830,000 | 44,356,000 | 43,112,000 | 45,541,000 | 45,781,000 | 45,604,000 | 31,759,000 | 33,252,000 | 34,284,000 | 34,760,000 | 31,989,000 | 33,139,000 | 34,307,000 | 33,743,000 | 32,920,000 | 33,124,000 | 35,444,000 | 36,344,000 | 6,650,000 | 6,650,000 | 6,650,000 | 6,650,000 | 6,650,000 | 6,650,000 | 6,650,000 | 6,650,000 |
goodwill | 40,336,000 | 40,336,000 | 40,336,000 | 40,336,000 | 40,336,000 | 40,336,000 | 40,336,000 | 40,336,000 | 40,336,000 | 40,336,000 | 40,208,000 | 39,655,000 | 39,615,000 | 37,523,000 | 37,523,000 | 37,084,000 | 36,983,000 | 36,983,000 | 26,051,000 | 26,051,000 | 26,109,000 | 23,857,000 | 23,857,000 | 23,857,000 | 23,857,000 | 23,857,000 | 23,777,000 | 22,559,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 13,839,000 | 28,047,000 | 28,072,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 | 12,005,000 |
restricted cash | 551,000 | 551,000 | 551,000 | 551,000 | 550,000 | 585,000 | 592,000 | 588,000 | 583,000 | 586,000 | 582,000 | 584,000 | 520,000 | 522,000 | 198,000 | 204,000 | 214,000 | 211,000 | 210,000 | 268,000 | 269,000 | 270,000 | 260,000 | 253,000 | 242,000 | 256,000 | 251,000 | 255,000 | 191,000 | 192,000 | 192,000 | 177,000 | 206,000 | 9,579,000 | 9,554,000 | 9,553,000 | 9,553,000 | 143,000 | 143,000 | 143,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 |
other assets | 3,415,000 | 3,353,000 | 2,802,000 | 2,731,000 | 2,147,000 | 2,221,000 | 1,771,000 | 1,958,000 | 2,060,000 | 1,353,000 | 2,441,000 | 2,036,000 | 2,080,000 | 3,828,000 | 4,886,000 | 5,057,000 | 5,192,000 | 5,835,000 | 6,834,000 | 9,590,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||||||
total assets | 411,062,000 | 413,228,000 | 432,307,000 | 444,257,000 | 489,638,000 | 491,050,000 | 476,985,000 | 466,777,000 | 452,406,000 | 466,826,000 | 501,180,000 | 514,820,000 | 528,217,000 | 542,991,000 | 544,511,000 | 541,288,000 | 546,711,000 | 566,621,000 | 563,172,000 | 557,415,000 | 541,223,000 | 368,511,000 | 353,552,000 | 344,742,000 | 156,784,000 | 151,736,000 | 144,833,000 | 142,907,000 | 127,859,000 | 130,697,000 | 91,446,000 | 79,879,000 | 78,952,000 | 83,565,000 | 75,093,000 | 77,738,000 | 80,322,000 | 76,730,000 | 102,092,000 | 100,453,000 | 48,834,000 | 55,638,000 | 59,342,000 | 61,366,000 | 63,277,000 | 61,141,000 | 62,862,000 | 33,997,000 |
liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 9,066,000 | 9,988,000 | 11,597,000 | 9,863,000 | 8,072,000 | 7,686,000 | 6,239,000 | 5,874,000 | 9,976,000 | 12,872,000 | 8,972,000 | 9,880,000 | 12,861,000 | 9,942,000 | 10,625,000 | 16,892,000 | 10,605,000 | 13,337,000 | 14,894,000 | 12,563,000 | 11,597,000 | 9,653,000 | 9,519,000 | 8,675,000 | 6,621,000 | 5,506,000 | 5,691,000 | 7,380,000 | 3,859,000 | 4,711,000 | 2,676,000 | 3,480,000 | 4,269,000 | 3,391,000 | 3,396,000 | 3,599,000 | 3,475,000 | 3,065,000 | 3,464,000 | 3,339,000 | 2,536,000 | 1,644,000 | 1,949,000 | 1,203,000 | 1,371,000 | 1,128,000 | 1,036,000 | 1,741,000 |
accrued compensation | 20,545,000 | 38,107,000 | 23,237,000 | 19,056,000 | 14,067,000 | 38,333,000 | 29,915,000 | 25,004,000 | 14,565,000 | 19,703,000 | 16,664,000 | 14,441,000 | 12,082,000 | 16,902,000 | 14,312,000 | 14,631,000 | 11,418,000 | 26,042,000 | 24,243,000 | 16,710,000 | 10,495,000 | 18,466,000 | 13,791,000 | 11,089,000 | 6,127,000 | 12,484,000 | 10,278,000 | 7,490,000 | 4,860,000 | 9,156,000 | ||||||||||||||||||
accrued and other liabilities | 49,542,000 | 41,754,000 | 43,960,000 | 44,011,000 | 42,895,000 | 43,352,000 | 45,286,000 | 47,453,000 | 45,670,000 | 45,497,000 | 47,038,000 | 50,175,000 | 46,885,000 | 49,131,000 | 45,351,000 | 46,933,000 | 44,897,000 | 37,922,000 | 30,599,000 | 26,982,000 | 23,638,000 | 20,602,000 | 18,617,000 | 16,682,000 | 15,576,000 | 16,838,000 | 15,002,000 | 13,750,000 | 7,651,000 | 5,408,000 | 4,718,000 | 4,703,000 | 4,392,000 | 3,735,000 | 3,895,000 | 4,960,000 | 5,843,000 | 5,320,000 | 8,204,000 | 7,695,000 | 5,298,000 | 2,892,000 | 2,331,000 | 1,840,000 | 1,810,000 | 1,616,000 | 1,911,000 | 3,649,000 |
total current liabilities | 79,153,000 | 89,849,000 | 99,044,000 | 93,180,000 | 85,284,000 | 89,371,000 | 81,440,000 | 78,331,000 | 70,211,000 | 78,072,000 | 72,674,000 | 74,496,000 | 71,828,000 | 75,975,000 | 70,288,000 | 78,456,000 | 66,920,000 | 77,301,000 | 69,736,000 | 56,255,000 | 45,730,000 | 69,217,000 | 62,423,000 | 56,942,000 | 28,324,000 | 34,828,000 | 30,971,000 | 28,620,000 | 16,370,000 | 19,504,000 | 15,817,000 | 14,176,000 | 13,445,000 | 42,906,000 | 30,961,000 | 54,236,000 | 53,003,000 | 40,832,000 | 39,605,000 | 38,246,000 | 14,231,000 | 10,152,000 | 10,454,000 | 8,242,000 | 6,275,000 | 11,135,000 | 11,118,000 | 21,214,000 |
deferred tax liability | 130,000 | 181,000 | 117,000 | 131,000 | 129,000 | 164,000 | 202,000 | 50,000 | 43,000 | 136,000 | 140,000 | 51,000 | 13,000 | 25,000 | 194,000 | 415,000 | 678,000 | 810,000 | 945,000 | 1,299,000 | 1,187,000 | 1,313,000 | 1,502,000 | 1,973,000 | 2,013,000 | 2,310,000 | 2,571,000 | 2,968,000 | 3,447,000 | 3,693,000 | 4,415,000 | 4,933,000 | 5,950,000 | 5,894,000 | 5,934,000 | 6,057,000 | 6,896,000 | 7,729,000 | ||||||||||
operating lease liabilities, less current portion | 17,837,000 | 19,679,000 | ||||||||||||||||||||||||||||||||||||||||||||||
other liabilities | 407,000 | 257,000 | 634,000 | 636,000 | 644,000 | 645,000 | 96,946,000 | 96,721,000 | 97,686,000 | 96,551,000 | 245,000 | 247,000 | 248,000 | 249,000 | 251,000 | 252,000 | 253,000 | 455,000 | 456,000 | 473,000 | 480,000 | 240,000 | 747,000 | 1,614,000 | 1,743,000 | 4,121,000 | 2,263,000 | 2,595,000 | 2,775,000 | 1,133,000 | 1,518,000 | 1,524,000 | 1,384,000 | 1,315,000 | 1,313,000 | 1,349,000 | 1,530,000 | 1,222,000 | 1,119,000 | 861,000 | 28,000 | 28,000 | 28,000 | 28,000 | 28,000 | |||
total liabilities | 97,527,000 | 110,127,000 | 121,167,000 | 116,887,000 | 110,289,000 | 112,617,000 | 203,739,000 | 202,108,000 | 196,181,000 | 205,498,000 | 107,046,000 | 109,607,000 | 108,196,000 | 112,080,000 | 107,832,000 | 97,739,000 | 89,167,000 | 100,745,000 | 91,025,000 | 77,572,000 | 69,677,000 | 90,832,000 | 84,908,000 | 83,975,000 | 55,400,000 | 52,736,000 | 47,290,000 | 49,741,000 | 32,237,000 | 34,769,000 | 47,058,000 | 50,927,000 | 45,559,000 | 89,519,000 | 75,268,000 | 65,752,000 | 65,462,000 | 56,969,000 | 65,312,000 | 67,943,000 | 28,374,000 | 26,144,000 | 25,439,000 | 24,593,000 | 23,810,000 | 19,843,000 | 21,823,000 | 35,463,000 |
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock: 0.001 par value... | ||||||||||||||||||||||||||||||||||||||||||||||||
common stock: 0.001 par value... | 51,000 | 50,000 | 51,000 | 53,000 | 51,000 | 51,000 | 50,000 | 50,000 | 49,000 | 49,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | 51,000 | 51,000 | 49,000 | 47,000 | 47,000 | 42,000 | 42,000 | 42,000 | 42,000 | 41,000 | 41,000 | 39,000 | 36,000 | 35,000 | 29,000 | 23,000 | 21,000 | 21,000 | 21,000 | 21,000 | 19,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 1,000 |
additional paid-in capital | 1,052,306,000 | 1,043,925,000 | 1,036,091,000 | 1,028,591,000 | 1,022,982,000 | 1,013,193,000 | 984,627,000 | 969,427,000 | 959,734,000 | 946,511,000 | 936,954,000 | 923,514,000 | 912,291,000 | 898,806,000 | 886,909,000 | 875,213,000 | 865,419,000 | 853,683,000 | 843,226,000 | 838,089,000 | 828,308,000 | 632,253,000 | 621,961,000 | 612,228,000 | 447,888,000 | 437,976,000 | 432,471,000 | 425,418,000 | 419,959,000 | 412,010,000 | 356,427,000 | 321,144,000 | 309,898,000 | 264,204,000 | 238,215,000 | 236,617,000 | 236,122,000 | 235,673,000 | 235,087,000 | 226,593,000 | 203,284,000 | 202,564,000 | 202,213,000 | 201,595,000 | 201,104,000 | 200,661,000 | 200,397,000 | 9,672,000 |
accumulated other comprehensive loss | -6,272,000 | -5,515,000 | -5,955,000 | -6,113,000 | -7,089,000 | -8,569,000 | -7,179,000 | -7,964,000 | -8,108,000 | -6,963,000 | -8,670,000 | -8,450,000 | -7,439,000 | -7,503,000 | -8,809,000 | -7,182,000 | -5,090,000 | -4,670,000 | -4,093,000 | -3,156,000 | -3,599,000 | -2,096,000 | -4,352,000 | -5,314,000 | -6,910,000 | -5,205,000 | -5,934,000 | -5,071,000 | -5,002,000 | -4,278,000 | -3,988,000 | -4,108,000 | -2,482,000 | -2,345,000 | -2,198,000 | -2,724,000 | -3,395,000 | -3,659,000 | -1,831,000 | -1,408,000 | ||||||||
accumulated deficit | -732,550,000 | -735,359,000 | -719,047,000 | -695,161,000 | -636,595,000 | -626,242,000 | -704,252,000 | -696,844,000 | -695,450,000 | -678,269,000 | -534,202,000 | -509,903,000 | -484,883,000 | -460,444,000 | -441,473,000 | -424,534,000 | -402,837,000 | -383,189,000 | -367,038,000 | -355,141,000 | -353,214,000 | -352,527,000 | -349,012,000 | -346,194,000 | -339,636,000 | -333,813,000 | -329,036,000 | -327,223,000 | -319,376,000 | -311,845,000 | -308,090,000 | -288,120,000 | -274,058,000 | -268,022,000 | -236,351,000 | -222,083,000 | -218,115,000 | -212,553,000 | -197,071,000 | -193,305,000 | -182,836,000 | -173,082,000 | -168,322,000 | -164,834,000 | -161,649,000 | -159,375,000 | -159,370,000 | -160,583,000 |
total stockholders’ equity | 313,535,000 | 303,101,000 | 311,140,000 | 327,370,000 | 379,349,000 | 378,433,000 | 273,246,000 | 264,669,000 | 256,225,000 | 261,328,000 | 394,134,000 | 405,213,000 | 420,021,000 | 430,911,000 | 436,679,000 | 443,549,000 | 457,544,000 | 465,876,000 | 472,147,000 | 479,843,000 | 471,546,000 | 277,679,000 | 268,644,000 | 99,000,000 | 95,928,000 | 44,388,000 | 28,952,000 | 33,393,000 | -175,000 | 11,986,000 | 14,860,000 | 19,761,000 | 36,780,000 | 32,510,000 | 20,460,000 | 29,494,000 | 33,903,000 | 36,773,000 | 39,467,000 | 41,298,000 | 41,039,000 | |||||||
total liabilities and stockholders’ equity | 411,062,000 | 413,228,000 | 432,307,000 | 444,257,000 | 489,638,000 | 491,050,000 | 476,985,000 | 466,777,000 | 452,406,000 | 466,826,000 | 501,180,000 | 514,820,000 | 528,217,000 | 542,991,000 | 544,511,000 | 541,288,000 | 546,711,000 | 566,621,000 | 563,172,000 | 557,415,000 | 541,223,000 | 368,511,000 | 353,552,000 | 344,742,000 | 156,784,000 | 151,736,000 | 144,833,000 | 142,907,000 | 127,859,000 | 130,697,000 | 91,446,000 | 79,879,000 | 78,952,000 | 75,093,000 | 77,738,000 | 80,322,000 | 76,730,000 | 102,092,000 | 100,453,000 | 48,834,000 | 55,638,000 | 59,342,000 | 61,366,000 | 63,277,000 | ||||
contingent consideration | 161,000 | 160,000 | 160,000 | 160,000 | 174,000 | 1,816,000 | 1,672,000 | 801,000 | 207,000 | 271,000 | 492,000 | 526,000 | 638,000 | 735,000 | 948,000 | 618,000 | 963,000 | 821,000 | 1,074,000 | 1,037,000 | 2,313,000 | |||||||||||||||||||||||||||
operating leases right-of-use assets | 24,047,000 | 25,372,000 | 26,390,000 | 24,340,000 | 25,823,000 | 27,188,000 | 28,591,000 | 29,891,000 | 30,973,000 | 32,118,000 | 33,431,000 | 34,689,000 | 35,843,000 | 15,841,000 | 17,122,000 | 17,993,000 | 18,316,000 | 17,859,000 | 18,289,000 | 15,228,000 | 15,802,000 | 16,416,000 | 17,004,000 | 4,730,000 | 2,244,000 | 2,657,000 | 2,506,000 | |||||||||||||||||||||
accrued litigation settlement expense | 20,250,000 | 20,250,000 | 20,250,000 | |||||||||||||||||||||||||||||||||||||||||||||
operating lease liability, less current portion | 21,212,000 | 22,780,000 | 24,072,000 | 22,263,000 | 23,841,000 | 25,386,000 | 26,893,000 | 28,278,000 | 29,252,000 | 30,589,000 | 32,006,000 | 33,406,000 | 34,708,000 | 16,065,000 | 16,729,000 | 17,394,000 | 17,876,000 | 17,783,000 | 18,462,000 | 16,069,000 | 16,539,000 | 17,025,000 | 17,503,000 | |||||||||||||||||||||||||
deferred payments for intangible assets | 1,310,000 | 1,620,000 | 1,348,000 | 2,461,000 | 4,735,000 | 4,224,000 | 4,089,000 | 2,418,000 | 2,522,000 | 2,877,000 | 4,959,000 | 5,041,000 | 2,084,000 | 1,968,000 | 3,640,000 | 3,560,000 | 3,480,000 | 5,400,000 | 5,311,000 | 5,207,000 | 5,103,000 | 4,930,000 | ||||||||||||||||||||||||||
common stock warrant liability | 25,000 | 32,000 | 50,000 | 64,000 | 112,000 | 139,000 | 195,000 | 283,000 | 420,000 | 447,000 | 532,000 | 1,681,000 | 1,017,000 | 6,607,000 | 6,940,000 | 11,286,000 | 10,521,000 | 10,003,000 | 11,612,000 | 16,800,000 | 13,247,000 | 18,712,000 | 10,431,000 | 2,203,000 | 2,759,000 | 5,208,000 | 6,736,000 | 8,122,000 | ||||||||||||||||||||
refund liability - cms advance payment | 20,496,000 | |||||||||||||||||||||||||||||||||||||||||||||||
deferred revenue - cms advance payment | 20,496,000 | 20,496,000 | ||||||||||||||||||||||||||||||||||||||||||||||
total stockholders' equity | 260,767,000 | 101,384,000 | 97,543,000 | 93,166,000 | 95,622,000 | |||||||||||||||||||||||||||||||||||||||||||
prepaid and other assets | 1,795,000 | 1,479,000 | 1,593,000 | 2,455,000 | 1,352,000 | 1,530,000 | 1,457,000 | 1,463,000 | 1,186,000 | 846,000 | 1,779,000 | 807,000 | 1,341,000 | 960,000 | 674,000 | 747,000 | 542,000 | 718,000 | 3,319,000 | |||||||||||||||||||||||||||||
deferred revenue | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | 42,000 | 58,000 | 65,000 | 137,000 | 142,000 | 136,000 | 500,000 | 488,000 | 505,000 | 673,000 | 674,000 | |||||||||||||||||||||||||||||
deferred purchase consideration | 190,000 | 367,000 | 378,000 | 577,000 | 407,000 | 2,514,000 | 7,004,000 | 6,463,000 | 5,445,000 | 5,942,000 | 5,807,000 | |||||||||||||||||||||||||||||||||||||
derivative liability | 14,600,000 | 1,370,000 | 1,000,000 | 1,510,000 | ||||||||||||||||||||||||||||||||||||||||||||
current portion of long-term debt | 15,721,000 | 22,846,000 | 17,902,000 | 18,135,000 | 4,419,000 | 2,866,000 | 3,594,000 | 2,380,000 | 1,056,000 | 5,961,000 | 5,798,000 | |||||||||||||||||||||||||||||||||||||
deferred rent, net of current portion | 470,000 | 579,000 | 686,000 | 802,000 | 913,000 | 1,018,000 | 1,113,000 | 1,205,000 | 1,301,000 | 1,190,000 | 1,526,000 | 1,347,000 | 1,426,000 | 1,490,000 | 1,554,000 | 1,619,000 | 1,684,000 | 1,734,000 | 1,784,000 | |||||||||||||||||||||||||||||
deferred revenue, net of current portion | 691,000 | 701,000 | 711,000 | 721,000 | 730,000 | 740,000 | 750,000 | 760,000 | 759,000 | 744,000 | 749,000 | 693,000 | 703,000 | 724,000 | 417,000 | 458,000 | 471,000 | 1,004,000 | 1,006,000 | |||||||||||||||||||||||||||||
long-term debt | 13,384,000 | 13,337,000 | 9,729,000 | 18,338,000 | 21,174,000 | 1,098,000 | 8,496,000 | 10,072,000 | 11,368,000 | 12,887,000 | 12,125,000 | 13,389,000 | 14,609,000 | 6,930,000 | 8,338,000 | |||||||||||||||||||||||||||||||||
stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||
total caredx, inc. stockholders’ equity | 95,928,000 | 19,482,000 | ||||||||||||||||||||||||||||||||||||||||||||||
noncontrolling interest | 180,000 | 136,000 | 155,000 | 227,000 | 279,000 | 574,000 | 611,000 | |||||||||||||||||||||||||||||||||||||||||
accrued payroll liabilities | 8,017,000 | 5,576,000 | 3,707,000 | 5,013,000 | 4,453,000 | 3,440,000 | 3,000,000 | 3,851,000 | 3,725,000 | 2,944,000 | 1,609,000 | 2,366,000 | 2,192,000 | 2,051,000 | 1,295,000 | 1,684,000 | 1,403,000 | 1,190,000 | ||||||||||||||||||||||||||||||
current debt | 461,000 | 15,000,000 | 33,890,000 | 32,386,000 | ||||||||||||||||||||||||||||||||||||||||||||
total caredx, inc. stockholders' equity | 44,388,000 | 28,952,000 | 33,393,000 | -311,000 | 11,831,000 | 14,633,000 | 36,206,000 | 31,899,000 | ||||||||||||||||||||||||||||||||||||||||
other noncurrent assets | 20,000 | 30,000 | 20,000 | 20,000 | 49,000 | 25,000 | ||||||||||||||||||||||||||||||||||||||||||
liabilities and stockholders’ (deficit) equity | ||||||||||||||||||||||||||||||||||||||||||||||||
accrued royalties | 294,000 | 304,000 | 287,000 | 263,000 | 310,000 | 261,000 | 232,000 | 242,000 | 252,000 | 268,000 | 255,000 | 241,000 | 297,000 | 3,526,000 | ||||||||||||||||||||||||||||||||||
total caredx, inc. stockholders’ (deficit) equity | -6,134,000 | |||||||||||||||||||||||||||||||||||||||||||||||
total stockholders’ (deficit) equity | -5,954,000 | |||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and stockholders’ (deficit) equity | 83,565,000 | |||||||||||||||||||||||||||||||||||||||||||||||
deferred purchase consideration, net of current portion | 2,880,000 | |||||||||||||||||||||||||||||||||||||||||||||||
liabilities, convertible preferred stock, and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||
long-term portion of debt and other, net of current portion | 5,451,000 | |||||||||||||||||||||||||||||||||||||||||||||||
convertible preferred stock warrant liability | 808,000 | |||||||||||||||||||||||||||||||||||||||||||||||
convertible preferred stock: 0.001 par value... | 149,444,000 | |||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, convertible preferred stock and stockholders’ equity | 61,141,000 | 62,862,000 | ||||||||||||||||||||||||||||||||||||||||||||||
liabilities, convertible preferred stock, and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||||||||
current portion of long-term debt, and subordinated convertible note | 10,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ deficit: | ||||||||||||||||||||||||||||||||||||||||||||||||
total stockholders’ deficit | -150,910,000 | |||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, convertible preferred stock and stockholders’ deficit | 33,997,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||
net income | 2,809,000 | -4,762,000 | -5,000 | ||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | 9,803,000 | 8,091,000 | 8,418,000 | 9,424,000 | 8,931,000 | 26,198,000 | 13,694,000 | 13,170,000 | 13,344,000 | 9,961,000 | 12,671,000 | 12,700,000 | 13,754,000 | 12,126,000 | 11,200,000 | 12,593,000 | 10,634,000 | 9,498,000 | 10,638,000 | 9,398,000 | 6,547,000 | 5,977,000 | 6,748,000 | 6,417,000 | 4,259,000 | -16,987,583 | 5,965,000 | 4,992,000 | 6,053,000 | 1,861,000 | 2,511,000 | 706,000 | 428,000 | 430,000 | 495,000 | 391,000 | 487,000 | 699,000 | 366,000 | 446,000 | 313,000 | 336,000 | 412,000 | 280,000 | 185,000 | 165,000 | |
depreciation and amortization | 3,899,000 | 3,882,000 | 3,814,000 | 3,722,000 | 3,600,000 | 3,361,000 | 3,469,000 | 3,543,000 | 3,821,000 | 3,631,000 | 3,662,000 | 3,666,000 | 3,427,000 | 3,206,000 | 3,026,000 | 2,744,000 | 2,619,000 | 2,496,000 | 2,199,000 | 2,152,000 | 1,950,000 | 1,954,000 | 1,803,000 | 1,630,000 | 1,619,000 | -3,834,477 | 1,460,000 | 1,219,000 | 1,161,000 | 1,176,000 | 1,014,000 | 986,000 | 1,039,000 | 1,019,000 | 919,000 | 887,000 | 934,000 | 725,000 | 1,098,000 | 836,000 | 261,000 | 221,000 | 217,000 | 193,000 | 165,000 | 158,000 | 132,000 |
amortization of right-of-use assets | 1,419,000 | 1,378,000 | 1,349,000 | 1,331,000 | 1,340,000 | 1,327,000 | 1,420,000 | 1,414,000 | 1,402,000 | 1,418,000 | 1,368,000 | 1,315,000 | 1,337,000 | 1,292,000 | 1,298,000 | 907,000 | 915,000 | 901,000 | 821,000 | 689,000 | 677,000 | 642,000 | 640,000 | 644,000 | 612,000 | ||||||||||||||||||||||
loss on disposal of asset | 119,000 | 7,000 | |||||||||||||||||||||||||||||||||||||||||||||
revaluation of contingent consideration to estimated fair value | 156,000 | 0 | 501,000 | 46,000 | 170,000 | 232,000 | 210,000 | 319,000 | 946,000 | 1,243,000 | 124,000 | 364,000 | -103,000 | 266,000 | 500,000 | 64,000 | -574,000 | 156,000 | -147,000 | -44,000 | 8,000 | 35,000 | 76,000 | 190,000 | 0 | 0 | 873,000 | 144,000 | 871,000 | 594,000 | -64,000 | -221,000 | -34,000 | -112,000 | -97,000 | -213,000 | 330,000 | -345,000 | 142,000 | -253,000 | |||||||
amortization of premium and accretion of discount on marketable securities | 912,000 | ||||||||||||||||||||||||||||||||||||||||||||||
other | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | -2,078,000 | 5,306,000 | 19,551,000 | 4,304,000 | -6,640,000 | 1,809,000 | -343,000 | -6,008,000 | -9,199,000 | 665,000 | 126,000 | 7,561,000 | 7,664,000 | 4,178,000 | -276,000 | -4,971,000 | -5,591,000 | -2,836,000 | -8,161,000 | -4,664,000 | -8,755,000 | -5,043,000 | -3,459,000 | -4,246,000 | 2,346,000 | 7,803,325 | -1,860,000 | -3,174,000 | -2,782,000 | -137,000 | -1,550,000 | -1,674,000 | -606,000 | 207,000 | -164,000 | 424,000 | -576,000 | 1,737,000 | 292,000 | -837,000 | -145,000 | -126,000 | -535,000 | 88,000 | 893,000 | -938,000 | -24,000 |
inventory | -346,000 | 2,034,000 | -252,000 | -4,067,000 | -2,674,000 | -1,312,000 | 519,000 | 1,049,000 | -1,274,000 | -704,000 | 746,000 | -1,205,000 | 1,217,000 | -601,000 | 248,000 | -1,446,000 | -1,060,000 | 2,490,000 | -4,086,000 | -1,275,000 | -4,056,000 | 412,000 | -926,000 | -1,339,000 | -1,343,000 | 1,325,730 | -776,000 | -179,000 | -372,000 | 5,000 | 25,000 | 137,000 | 196,000 | 563,000 | 210,000 | -218,000 | 470,000 | 167,000 | 89,000 | 65,000 | 171,000 | 49,000 | -84,000 | 43,000 | -88,000 | -190,000 | 118,000 |
prepaid and other assets | -2,884,000 | 3,946,000 | -4,189,000 | -1,386,000 | -2,784,000 | 921,000 | -1,084,000 | 661,000 | 108,000 | -775,000 | 441,000 | 586,000 | 1,515,000 | -652,000 | 117,000 | 53,000 | -567,000 | -3,072,000 | 2,131,000 | -575,000 | -3,628,000 | 640,000 | -16,000 | -120,000 | -545,000 | 785,000 | 322,000 | -541,000 | -328,000 | 122,000 | 214,000 | -510,000 | 147,000 | -42,000 | 56,000 | -245,000 | -291,000 | 445,000 | 282,000 | 563,000 | -430,000 | -285,000 | 72,000 | -180,000 | |||
operating leases liabilities | -1,559,000 | -1,502,000 | -1,470,000 | -1,483,000 | -1,372,000 | -1,411,000 | -1,344,000 | -1,333,000 | -428,000 | -993,000 | -969,000 | -726,000 | -631,000 | -320,000 | -375,000 | -377,000 | -344,000 | -1,018,000 | 57,000 | -475,000 | |||||||||||||||||||||||||||
accounts payable | -338,000 | -2,378,000 | 1,561,000 | 1,248,000 | 377,000 | 1,589,000 | 221,000 | -4,023,000 | -2,897,000 | 3,894,000 | -1,004,000 | -2,576,000 | 2,590,000 | -357,000 | -6,183,000 | 6,035,000 | -1,549,000 | 1,389,000 | -1,159,000 | 63,000 | 1,496,000 | 558,000 | 1,262,000 | 812,000 | 1,757,000 | -1,001,649 | -2,282,000 | 3,734,000 | -449,000 | 695,000 | -1,058,000 | -640,000 | 835,000 | 92,000 | -222,000 | 40,000 | 382,000 | 370,000 | -654,000 | -1,156,000 | 820,000 | -302,000 | 907,000 | -358,000 | 242,000 | 306,000 | -919,000 |
accrued compensation | -17,810,000 | 14,593,000 | 3,865,000 | 4,779,000 | -24,082,000 | 8,428,000 | 4,735,000 | 10,324,000 | -4,820,000 | 2,991,000 | 2,192,000 | 2,360,000 | -4,888,000 | 2,359,000 | 680,000 | 2,344,000 | -14,634,000 | 4,805,000 | 4,106,000 | 6,267,000 | -7,662,000 | 4,236,000 | 2,784,000 | 4,631,000 | -5,914,000 | -1,034,885 | 2,919,000 | 2,368,000 | -4,249,000 | ||||||||||||||||||
accrued and other liabilities | 10,372,000 | -8,850,000 | -2,000 | -764,000 | 6,308,000 | -96,465,000 | -1,889,000 | 2,136,000 | 557,000 | 93,070,000 | -3,751,000 | 2,641,000 | -2,352,000 | 4,845,000 | -1,097,000 | -337,000 | 7,916,000 | 3,002,000 | 3,042,000 | 2,985,000 | 1,661,000 | 1,330,000 | -143,000 | 1,676,000 | 48,000 | -2,474,971 | 1,270,000 | 1,006,000 | 202,000 | 299,000 | 367,000 | -562,000 | 654,000 | -80,000 | -139,000 | -1,109,000 | 358,000 | -2,698,000 | 440,000 | -247,000 | 2,400,000 | 541,000 | 425,000 | 78,000 | 196,000 | 43,000 | -1,796,000 |
net cash from operating activities | 4,333,000 | 21,363,000 | 37,358,000 | 9,895,000 | -26,584,000 | 21,889,000 | 12,522,000 | 18,949,000 | -15,312,000 | -8,381,000 | -10,179,000 | -499,000 | 671,000 | 7,185,000 | -7,079,000 | -3,877,000 | -21,468,000 | 4,166,000 | 382,000 | 9,788,000 | -33,630,000 | 7,181,000 | 5,207,000 | 24,098,000 | -3,055,000 | 1,683,231 | 605,000 | 3,576,000 | -5,867,000 | 1,998,000 | 399,000 | -1,886,000 | -4,518,000 | -2,148,000 | -2,221,000 | -3,197,000 | -6,741,000 | -3,061,000 | -1,203,000 | -6,067,000 | -6,192,000 | -3,976,000 | -3,029,000 | -1,733,000 | -1,014,000 | -722,000 | -3,661,000 |
capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,704,000 | 0 | -409,000 | -18,000 | -543,000 | -960,000 | -614,000 | -399,000 | -62,000 | -86,000 | -6,000 | -26,000 | -68,000 | 78,000 | -351,000 | -167,000 | -109,000 | -76,000 | -390,000 | -369,000 | -364,000 | -400,000 | -169,000 |
free cash flows | 4,333,000 | 21,363,000 | 37,358,000 | 9,895,000 | -26,584,000 | 21,889,000 | 12,522,000 | 18,949,000 | -15,312,000 | -8,381,000 | -10,179,000 | -499,000 | 671,000 | 7,185,000 | -7,079,000 | -3,877,000 | -21,468,000 | 4,166,000 | 382,000 | 9,788,000 | -33,630,000 | 7,181,000 | 5,207,000 | 24,098,000 | -4,759,000 | 1,683,231 | 196,000 | 3,558,000 | -6,410,000 | 1,038,000 | -215,000 | -2,285,000 | -4,580,000 | -2,234,000 | -2,227,000 | -3,223,000 | -6,809,000 | -2,983,000 | -1,554,000 | -6,234,000 | -6,301,000 | -4,052,000 | -3,419,000 | -2,102,000 | -1,378,000 | -1,122,000 | -3,830,000 |
investing activities: | |||||||||||||||||||||||||||||||||||||||||||||||
purchases of marketable securities | -39,850,000 | ||||||||||||||||||||||||||||||||||||||||||||||
maturities of marketable securities | 54,728,000 | 25,072,000 | |||||||||||||||||||||||||||||||||||||||||||||
additions of property and equipment | -3,819,000 | ||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities | 11,059,000 | -34,913,000 | 12,349,000 | 23,397,000 | 1,325,000 | -2,111,000 | -14,406,000 | -11,626,000 | 27,660,000 | 41,367,000 | -1,498,000 | 15,348,000 | -14,771,000 | 2,475,000 | -75,735,000 | 790,000 | -156,032,000 | -7,782,000 | 20,202,000 | 16,213,000 | 19,079,000 | -90,474,000 | -4,236,000 | -3,980,000 | -1,704,000 | 21,214,421 | -3,515,000 | -17,179,000 | -543,000 | -960,000 | -614,000 | -5,601,000 | -754,000 | -5,061,000 | -975,000 | -24,000 | -104,000 | 77,000 | -351,000 | -20,734,000 | -109,000 | -76,000 | -390,000 | -594,000 | -199,000 | ||
financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock under employee stock purchase plan | 991,000 | 0 | 0 | 1,399,000 | 873,000 | 0 | 865,000 | 0 | 532,000 | 0 | 1,039,000 | 0 | 456,000 | -1,000 | 1,232,000 | 0 | 999,000 | 0 | 1,301,000 | 171,000 | 667,000 | 286,000 | 480,000 | 244,000 | 358,000 | -759,240 | 419,000 | 0 | 341,000 | 255,000 | 0 | 0 | 32,000 | 49,000 | 0 | 44,000 | 129,000 | ||||||||||
taxes paid related to net share settlement of restricted stock units | -2,511,000 | -1,670,000 | -1,147,000 | -6,239,000 | -3,065,000 | -3,567,000 | -2,259,000 | -3,598,000 | -668,000 | -545,000 | -350,000 | -1,508,000 | -656,000 | -390,000 | -1,651,000 | -2,410,000 | -1,482,000 | -2,689,000 | -6,425,000 | -6,638,000 | -2,313,000 | -526,000 | -466,000 | -2,030,000 | -1,507,000 | 3,999,847 | -29,000 | -1,597,000 | -2,378,000 | ||||||||||||||||||
proceeds from exercise of stock options | 109,000 | 1,413,000 | 232,000 | 1,029,000 | 3,049,000 | 5,614,000 | 3,191,000 | 123,000 | 8,000 | 13,000 | 100,000 | 5,000 | 2,000 | 286,000 | 138,000 | 413,000 | 1,598,000 | 1,855,000 | 1,894,000 | 6,833,000 | 2,193,000 | 4,242,000 | 1,647,000 | 1,962,000 | 155,000 | -3,241,447 | 476,000 | 1,404,000 | 1,365,000 | 891,000 | 410,000 | 99,000 | 80,000 | 10,000 | 0 | 3,000 | 6,000 | 1,000 | 3,000 | 31,000 | 11,000 | 14,000 | 0 | ||||
payment of contingent consideration | -1,500,000 | 0 | 0 | 0 | -1,500,000 | -625,000 | -375,000 | 0 | 0 | -250,000 | -1,625,000 | -750,000 | 0 | -250,000 | |||||||||||||||||||||||||||||||||
net cash from financing activities | -2,911,000 | -12,462,000 | -26,478,000 | -53,811,000 | -643,000 | -903,000 | 1,422,000 | -4,850,000 | -1,275,000 | -26,877,000 | -25,000 | -1,566,000 | -1,138,000 | -2,372,000 | -1,031,000 | -1,997,000 | 865,000 | -834,000 | -3,133,000 | 381,000 | 189,228,000 | 3,964,000 | 1,224,000 | 158,696,000 | -735,000 | 213,868 | 746,000 | -272,000 | -688,000 | 37,312,000 | 10,198,000 | 5,076,000 | -2,318,000 | 17,920,000 | 108,000 | 220,000 | 1,756,000 | -2,134,000 | 6,686,000 | 20,210,000 | 165,000 | -14,000 | 479,000 | 11,000 | 3,932,000 | -1,301,000 | 35,036,000 |
effect of exchange rate changes on cash and cash equivalents | 13,000 | 6,000 | -6,000 | -13,000 | -77,000 | 407,000 | 84,000 | 15,000 | 26,000 | 112,000 | -106,000 | -93,000 | -25,000 | 45,000 | -146,000 | -52,000 | -82,000 | -23,000 | 210,000 | 201,000 | 415,000 | -552,000 | 492,151 | -382,000 | -24,000 | -87,000 | 64,000 | -12,000 | -67,000 | 17,000 | 208,000 | -40,000 | -82,000 | 18,000 | 111,000 | -11,000 | |||||||||||
net increase in cash, cash equivalents and restricted cash | 12,494,000 | -26,006,000 | 23,223,000 | -20,532,000 | -25,979,000 | 19,282,000 | -378,000 | 2,488,000 | 11,099,000 | 7,286,000 | -83,879,000 | -5,070,000 | -176,590,000 | -4,596,000 | 17,399,000 | 26,300,000 | 174,654,000 | -79,119,000 | 2,396,000 | -2,478,000 | -7,573,000 | ||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of period | 65,980,000 | 0 | 0 | 115,274,000 | 0 | 0 | 82,783,000 | ||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at end of period | 78,474,000 | 23,223,000 | -20,532,000 | 89,295,000 | -378,000 | 2,488,000 | 93,882,000 | ||||||||||||||||||||||||||||||||||||||||
asset impairments and write-downs | 0 | 0 | 0 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||
impairment of intangible asset and associated construction in progress | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
realized gain on sale of long-term marketable equity securities | |||||||||||||||||||||||||||||||||||||||||||||||
gain on settlement of obligation and recovery of written-off investment | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
revaluation of common stock warrant liability to estimated fair value | 0 | 0 | -3,000 | -7,000 | -18,000 | -14,000 | -48,000 | -27,000 | -56,000 | -88,000 | 65,000 | -27,000 | -79,000 | 664,000 | 405,000 | -1,386,000 | |||||||||||||||||||||||||||||||
accrued royalties | -294,000 | -9,000 | 16,000 | 24,000 | -47,000 | 50,000 | 28,000 | -10,000 | -10,000 | -16,000 | 13,000 | 14,000 | -56,000 | -3,228,000 | |||||||||||||||||||||||||||||||||
operating lease liabilities | -1,438,000 | -1,543,000 | |||||||||||||||||||||||||||||||||||||||||||||
deferred taxes | |||||||||||||||||||||||||||||||||||||||||||||||
purchase of corporate equity securities | 0 | -865,000 | 0 | -100,000 | |||||||||||||||||||||||||||||||||||||||||||
sale of corporate equity securities | |||||||||||||||||||||||||||||||||||||||||||||||
additions of capital expenditures | -1,971,000 | -1,305,000 | -1,007,000 | -1,630,000 | -1,522,000 | -1,685,000 | -1,790,000 | -1,487,000 | -1,594,000 | -1,617,000 | -2,362,000 | -2,771,000 | -3,277,000 | -4,846,000 | -4,648,000 | -8,463,000 | -5,848,000 | -3,623,000 | -2,838,000 | -1,250,000 | -440,000 | -3,236,000 | |||||||||||||||||||||||||
acquisition of intangible assets | 0 | -1,000,000 | -2,000,000 | -100,000 | 0 | 0 | -5,500,000 | -1,200,000 | 0 | -1,000,000 | 1,146,852 | -24,000 | |||||||||||||||||||||||||||||||||||
acquisition of business, net of cash acquired | 0 | -4,562,000 | 0 | -508,000 | -11,934,000 | 0 | 43,000 | -3,543,000 | 0 | ||||||||||||||||||||||||||||||||||||||
repurchase and retirement of common stock | -12,205,000 | -25,563,000 | 0 | 0 | 0 | -522,000 | -25,970,000 | -814,000 | -67,000 | -690,000 | |||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants | 0 | 0 | 0 | 0 | 9,000 | 39,000 | 0 | 304,000 | -104,895 | 0 | 27,000 | 78,000 | 2,000 | 10,472,000 | 499,000 | 25,000 | 954,000 | ||||||||||||||||||||||||||||||
cash, cash equivalents, and restricted cash at beginning of period | 0 | 90,443,000 | 0 | 0 | 0 | 348,696,000 | 0 | 0 | 0 | 134,939,000 | 0 | 0 | 0 | 38,479,000 | -64,743,192 | 0 | 0 | 64,808,000 | 0 | 0 | 0 | 26,474,000 | |||||||||||||||||||||||||
cash, cash equivalents, and restricted cash at end of period | 13,190,000 | 75,180,000 | 7,286,000 | -83,879,000 | -5,070,000 | 172,106,000 | -4,596,000 | 17,399,000 | 26,300,000 | 309,593,000 | -79,119,000 | 2,396,000 | 179,229,000 | 32,433,000 | -41,139,521 | -2,546,000 | -13,899,000 | 57,623,000 | 38,414,000 | 9,971,000 | -2,478,000 | 18,901,000 | |||||||||||||||||||||||||
supplemental disclosures of cash information | |||||||||||||||||||||||||||||||||||||||||||||||
cash paid for income taxes | |||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of non-cash operating, investing and financing information | |||||||||||||||||||||||||||||||||||||||||||||||
shares issued in lieu of payment | |||||||||||||||||||||||||||||||||||||||||||||||
operating lease right-of-use assets | |||||||||||||||||||||||||||||||||||||||||||||||
purchases of capital expenditures in accounts payable and accrued liabilities | |||||||||||||||||||||||||||||||||||||||||||||||
employee stock purchase plan shares included in accrued compensation | |||||||||||||||||||||||||||||||||||||||||||||||
contingent consideration | -1,439,558 | ||||||||||||||||||||||||||||||||||||||||||||||
net loss | 1,675,000 | -8,568,000 | -10,353,000 | -7,408,000 | -1,394,000 | -16,659,000 | -118,097,000 | -23,485,000 | -24,953,000 | -23,749,000 | -18,329,000 | -16,939,000 | -21,697,000 | -19,648,000 | -16,151,000 | -11,897,000 | -1,927,000 | -687,000 | -3,515,000 | -2,818,000 | -6,558,000 | -5,823,000 | 17,169,032 | -1,813,000 | -7,847,000 | -7,531,000 | -3,755,000 | -19,970,000 | -14,062,000 | -8,994,000 | -31,629,000 | -14,287,000 | -4,035,000 | -5,609,000 | -3,801,000 | -10,494,000 | -9,752,000 | -3,185,000 | -2,272,000 | ||||||||
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||
amortization of premium on short-term marketable securities | 931,000 | -1,318,000 | -773,000 | -603,000 | 453,000 | 401,000 | 139,000 | 199,000 | 293,000 | ||||||||||||||||||||||||||||||||||||||
other non-cash operating activities | 55,000 | 0 | -7,000 | ||||||||||||||||||||||||||||||||||||||||||||
change in deferred revenue | -174,000 | -10,000 | -10,000 | -9,000 | -10,000 | ||||||||||||||||||||||||||||||||||||||||||
change in deferred taxes | -244,000 | 143,000 | 7,000 | -93,000 | 485,000 | -58,000 | 1,000 | 59,000 | -217,000 | -790,000 | -144,000 | -159,000 | -286,000 | -144,000 | -249,000 | -308,000 | -322,000 | 1,152,720 | -637,000 | -252,000 | -265,000 | -439,000 | -276,000 | -545,000 | -347,000 | -1,406,000 | -140,000 | -271,000 | -271,000 | -393,000 | |||||||||||||||||
acquisitions of intangible asset | |||||||||||||||||||||||||||||||||||||||||||||||
purchases of short-term marketable securities | -17,071,000 | -14,808,000 | -52,472,000 | -17,101,000 | -49,973,000 | -35,466,000 | -57,746,000 | -9,034,000 | -56,860,000 | -48,961,000 | -86,310,000 | -31,703,000 | -100,529,000 | -34,391,000 | -148,522,000 | ||||||||||||||||||||||||||||||||
maturities of short-term marketable securities | 31,400,000 | 39,212,000 | 55,427,000 | 17,146,000 | 37,252,000 | 25,630,000 | 86,893,000 | 49,535,000 | 60,860,000 | 66,671,000 | 78,972,000 | 37,455,000 | 31,148,000 | 41,931,000 | 1,053,000 | 10,000,000 | 23,825,000 | ||||||||||||||||||||||||||||||
amortization of premium and accretion of discount on short-term marketable securities | 837,000 | -556,000 | 356,000 | -630,000 | 1,451,000 | ||||||||||||||||||||||||||||||||||||||||||
unrealized loss on long-term marketable equity securities | 333,000 | -53,000 | 905,000 | 966,000 | -271,000 | -21,000 | 507,000 | 1,576,000 | |||||||||||||||||||||||||||||||||||||||
cash paid for interest | |||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information | |||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of business, net of cash acquired | |||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of intangible assets | |||||||||||||||||||||||||||||||||||||||||||||||
payment of contingent consideration on acquisitions | -375,000 | ||||||||||||||||||||||||||||||||||||||||||||||
accretion of discount and amortization of premium on short-term marketable securities | -1,517,000 | ||||||||||||||||||||||||||||||||||||||||||||||
other non-cash items | |||||||||||||||||||||||||||||||||||||||||||||||
refund liability - cms advance payment | 0 | 0 | 0 | -20,496,000 | |||||||||||||||||||||||||||||||||||||||||||
purchases of long-term marketable securities | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common shares in public equity offering, net of issuance costs paid | 0 | 100,000 | 40,000 | 188,715,000 | 0 | -415,000 | |||||||||||||||||||||||||||||||||||||||||
principal payments on finance lease obligations | 0 | -3,000 | -29,000 | -34,000 | |||||||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -11,808,000 | 13,190,000 | -15,263,000 | -6,046,000 | -2,546,000 | -13,899,000 | -7,185,000 | ||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common shares in "at-the-market" equity offering, net of issuance costs paid | 0 | -15,000 | |||||||||||||||||||||||||||||||||||||||||||||
asset impairment and write-downs | |||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes on cash, cash equivalents and restricted cash | -34,000 | ||||||||||||||||||||||||||||||||||||||||||||||
investment in equity securities | 999,000 | ||||||||||||||||||||||||||||||||||||||||||||||
contingent payments related to acquisition of conexio genomics pty ltd. | |||||||||||||||||||||||||||||||||||||||||||||||
deferred payments for intangible assets | -7,172,793 | 226,000 | |||||||||||||||||||||||||||||||||||||||||||||
espp shares included in accrued compensation | |||||||||||||||||||||||||||||||||||||||||||||||
unrealized gain on long-term marketable equity securities | |||||||||||||||||||||||||||||||||||||||||||||||
amortization of inventory fair market value adjustment | 10,000 | 35,000 | 25,000 | 164,000 | 89,000 | 159,000 | 138,000 | 32,000 | 1,437,000 | 1,513,000 | |||||||||||||||||||||||||||||||||||||
loss on disposal of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||
revaluation of warrants and derivative liabilities to estimated fair value | |||||||||||||||||||||||||||||||||||||||||||||||
amortization of debt discount and noncash interest expense | 44,000 | 56,000 | 48,000 | 2,084,000 | 680,000 | 1,003,000 | 1,142,000 | 627,000 | -455,000 | 298,000 | 15,000 | 41,000 | |||||||||||||||||||||||||||||||||||
debt extinguishment expenses | |||||||||||||||||||||||||||||||||||||||||||||||
acquisition of business | 18,100,770 | -2,082,000 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from debt, net of issuance costs | 0 | 0 | 0 | 0 | 0 | 24,002,000 | 0 | 0 | 0 | 15,625,000 | |||||||||||||||||||||||||||||||||||||
principal payments on debt and finance lease obligations | -47,000 | -46,000 | -45,000 | -45,000 | -44,000 | -42,000 | -42,000 | ||||||||||||||||||||||||||||||||||||||||
change in short-term credit facility | |||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock upon conversion of convertible debt | |||||||||||||||||||||||||||||||||||||||||||||||
offering costs included in accounts payable | |||||||||||||||||||||||||||||||||||||||||||||||
common stock warrants issued upon debt financing | |||||||||||||||||||||||||||||||||||||||||||||||
loss on the write-off of fixed assets | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||
deferred revenue - cms advance payment | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
contingent payments related to the acquisition of conexio genomics pty ltd. | -76,000 | -64,000 | -52,000 | ||||||||||||||||||||||||||||||||||||||||||||
purchase of property and equipment | -1,704,000 | -409,000 | -18,000 | -543,000 | -960,000 | -614,000 | -399,000 | -62,000 | -86,000 | -6,000 | -26,000 | -68,000 | 78,000 | -351,000 | -167,000 | -109,000 | -76,000 | -390,000 | -369,000 | -364,000 | -400,000 | -169,000 | |||||||||||||||||||||||||
non-cash lease expense | -1,127,379 | 928,000 | -171,000 | 372,000 | |||||||||||||||||||||||||||||||||||||||||||
non-cash goodwill impairment | 0 | 0 | 0 | 1,958,000 | |||||||||||||||||||||||||||||||||||||||||||
prepaid and other current assets | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock, net of issuance costs | -367,000 | ||||||||||||||||||||||||||||||||||||||||||||||
principal payments on debt and capital lease obligations | -16,692,000 | -48,000 | -9,716,000 | -1,633,000 | -1,107,000 | -381,000 | 44,000 | -12,915,000 | -1,774,000 | -1,742,000 | -412,000 | -16,000 | |||||||||||||||||||||||||||||||||||
contingent payments related to acquisition | |||||||||||||||||||||||||||||||||||||||||||||||
change in bank overdraft obligation | -518,000 | 405,000 | |||||||||||||||||||||||||||||||||||||||||||||
deferred purchase consideration | 0 | 46,000 | 1,018,000 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
accrued interest capitalized to debt principal | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
operating lease right of use assets | |||||||||||||||||||||||||||||||||||||||||||||||
purchased of capital expenditures in accounts payable and accrued liabilities | |||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash as of: | |||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | -13,963,000 | 57,432,000 | 38,414,000 | 9,956,000 | -2,449,000 | 18,695,000 | |||||||||||||||||||||||||||||||||||||||||
restricted cash | 64,000 | 191,000 | 0 | 15,000 | -29,000 | 206,000 | |||||||||||||||||||||||||||||||||||||||||
total cash, cash equivalents, and restricted cash at the end of the period | |||||||||||||||||||||||||||||||||||||||||||||||
revaluation of common stock warrant liability and derivative liability to estimated fair value | -4,346,000 | 1,351,000 | 3,009,000 | 17,093,000 | 8,768,000 | -1,321,000 | 8,599,000 | -1,067,000 | -4,128,000 | ||||||||||||||||||||||||||||||||||||||
loss on conversion of jgb debt to shares of common stock | 0 | 0 | 2,806,000 | ||||||||||||||||||||||||||||||||||||||||||||
acquisition of noncontrolling interests, net of cash acquired | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from perceptive term loan, net of issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
change in short term credit facility | 0 | -452,000 | -225,000 | ||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of cash flow information: | |||||||||||||||||||||||||||||||||||||||||||||||
operating leases right-of-use assets | -413,000 | 151,000 | 2,506,000 | ||||||||||||||||||||||||||||||||||||||||||||
accrued purchase consideration | |||||||||||||||||||||||||||||||||||||||||||||||
total cash, cash equivalents and restricted cash at the end of period | -13,899,000 | 57,623,000 | 9,971,000 | -2,478,000 | 18,901,000 | ||||||||||||||||||||||||||||||||||||||||||
acquisition of allenex ab and noncontrolling interests, net of cash acquired | |||||||||||||||||||||||||||||||||||||||||||||||
perceptive term loan issuance costs | -584,000 | ||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation expense | |||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred revenue | -10,000 | -10,000 | -10,000 | -2,000 | -2,000 | -12,000 | -15,000 | -16,000 | -15,000 | -56,000 | -30,000 | -29,000 | -701,000 | -3,000 | |||||||||||||||||||||||||||||||||
acquisition of assets of conexio genomics pty ltd. | -48,000 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from private placement and subsequent financing, net of issuance costs | -3,000 | 6,000 | |||||||||||||||||||||||||||||||||||||||||||||
shares issued in lieu of cash payment | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
common stock issued for acquisition | |||||||||||||||||||||||||||||||||||||||||||||||
debt assumed as part of acquisition | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
conversion of convertible private placement and subsequent financing preferred stock to common stock | |||||||||||||||||||||||||||||||||||||||||||||||
common stock shares issued for contingent consideration | |||||||||||||||||||||||||||||||||||||||||||||||
goodwill impairment charge | |||||||||||||||||||||||||||||||||||||||||||||||
accrued payroll liabilities | 2,690,000 | 2,044,000 | -1,358,000 | 673,000 | 878,000 | 379,000 | -865,000 | 153,000 | 785,000 | 797,000 | -758,000 | 174,000 | 141,000 | 756,000 | -389,000 | 281,000 | 213,000 | ||||||||||||||||||||||||||||||
acquisition of intangible assets through illumina licensing agreement | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
acquisition of allenex ab, net of cash acquired | -4,902,000 | ||||||||||||||||||||||||||||||||||||||||||||||
acquisition of conexio genomics pty ltd. | -80,000 | -78,000 | -13,000 | ||||||||||||||||||||||||||||||||||||||||||||
repurchases of common stock under employee incentive plans | -556,000 | ||||||||||||||||||||||||||||||||||||||||||||||
contingent consideration shares issued | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
acquisition of allenex ab minority interest | |||||||||||||||||||||||||||||||||||||||||||||||
acquisition of allenex ab | -692,000 | ||||||||||||||||||||||||||||||||||||||||||||||
loss on conversion of debt to equity | |||||||||||||||||||||||||||||||||||||||||||||||
restricted cash on operating leases | |||||||||||||||||||||||||||||||||||||||||||||||
restricted cash collateral for debt | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuances of common stock under equity incentive plans | |||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | 10,919,000 | -3,128,000 | -3,083,000 | -5,071,000 | |||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of period | 0 | 0 | 0 | 17,258,000 | 0 | 0 | 0 | 29,888,000 | 0 | 0 | 0 | 36,431,000 | 0 | 0 | |||||||||||||||||||||||||||||||||
cash and cash equivalents at end of period | 10,919,000 | -3,128,000 | -3,083,000 | 12,187,000 | -5,007,000 | 5,121,000 | -6,608,000 | 23,752,000 | -4,066,000 | -2,940,000 | -2,091,000 | 38,985,000 | -2,617,000 | 31,176,000 | |||||||||||||||||||||||||||||||||
supplemental disclosures of noncash investing and financing activities | |||||||||||||||||||||||||||||||||||||||||||||||
property and equipment purchased under capital leases | |||||||||||||||||||||||||||||||||||||||||||||||
restricted cash collateral on lease | 0 | 2,000 | -36,000 | ||||||||||||||||||||||||||||||||||||||||||||
restricted cash collateral on debt | 0 | 0 | -9,375,000 | ||||||||||||||||||||||||||||||||||||||||||||
common shares issued as part of acquisition | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
common stock issuance costs accrued, not paid | |||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||
non-cash income tax benefit in connection with business acquisition | |||||||||||||||||||||||||||||||||||||||||||||||
payment for acquisitions, net of cash acquired | -194,000 | -30,000 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from initial public offering, net of underwriters’ discount | |||||||||||||||||||||||||||||||||||||||||||||||
payments of initial public offering costs | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from subordinated convertible debt, net of issuance costs | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -6,608,000 | -6,136,000 | -4,066,000 | -2,940,000 | -2,091,000 | 2,554,000 | -2,617,000 | 31,176,000 | |||||||||||||||||||||||||||||||||||||||
conversion of convertible preferred stock to common stock upon initial public offering | |||||||||||||||||||||||||||||||||||||||||||||||
conversion of convertible preferred stock warrants to common stock warrants upon initial public offering | |||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock for board of director services | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuances of common stock under employee stock purchase plan | 175,000 | ||||||||||||||||||||||||||||||||||||||||||||||
revaluation of warrants and derivatives to estimated fair value | |||||||||||||||||||||||||||||||||||||||||||||||
deferred revenue | |||||||||||||||||||||||||||||||||||||||||||||||
common stock issued in lieu of services | |||||||||||||||||||||||||||||||||||||||||||||||
amortization of debt discount and non-cash interest expense | -246,000 | 43,000 | 407,000 | ||||||||||||||||||||||||||||||||||||||||||||
revaluation of warrants to estimated fair value | |||||||||||||||||||||||||||||||||||||||||||||||
gain on remeasurement of embedded derivative | |||||||||||||||||||||||||||||||||||||||||||||||
non-cash income tax benefit | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
payment for acquisition, net of cash acquired | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from initial public offering, net of underwriters discount | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
payment of initial public offering costs | -17,000 | -2,807,000 | |||||||||||||||||||||||||||||||||||||||||||||
principal payments on debt and capital leases | 273,000 | -20,000 | -11,704,000 | ||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock under employee stock purchase plan | |||||||||||||||||||||||||||||||||||||||||||||||
net cash from provided by investing activities | -364,000 | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash income tax benefit in connection with business combinations | |||||||||||||||||||||||||||||||||||||||||||||||
purchase of investments | |||||||||||||||||||||||||||||||||||||||||||||||
sales of investments | |||||||||||||||||||||||||||||||||||||||||||||||
maturities of investments | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible preferred stock, net of issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
principal payments on debt | -1,353,000 | -1,348,000 | |||||||||||||||||||||||||||||||||||||||||||||
conversion of subordinated convertible note to common stock upon initial public offering | |||||||||||||||||||||||||||||||||||||||||||||||
common stock issued for services | |||||||||||||||||||||||||||||||||||||||||||||||
operating activities | |||||||||||||||||||||||||||||||||||||||||||||||
accretion of debt discount and noncash interest expense | |||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of warrants | |||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of embedded derivative | |||||||||||||||||||||||||||||||||||||||||||||||
change in estimated fair value of contingent consideration | |||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets | |||||||||||||||||||||||||||||||||||||||||||||||
investing activities | |||||||||||||||||||||||||||||||||||||||||||||||
financing activities | |||||||||||||||||||||||||||||||||||||||||||||||
repayment of capital lease obligations | |||||||||||||||||||||||||||||||||||||||||||||||
issuance costs in connection with loan modification |